Upon receiving the license, Boehringer will install the technology at its microbial facility in Vienna, Austria, which will be used for developing biopharmaceutical production processes.
Boehringer Ingelheim process science executive director Georg Klima said under the non-exclusive technology and commercial license option agreement, the company will leverage BaroFold’s high pressure refold technology on a variety of proteins under development at its Vienna facility.
"Innovation is what sets Boehringer Ingelheim apart from other biopharmaceutical and contract manufacturing companies and we look forward to realizing significant success with BaroFold’s technology," Klima added.
BaroFold president and CSO Matthew Seefeldt said, "Boehringer Ingelheim is a pioneer in biologic drug manufacturing and to extend our collaboration with them further enhances our ability to provide the global biotechnology arena with a novel refold technology."